NYSE:MED Medifast (MED) Stock Price, News & Analysis $14.71 +0.38 (+2.67%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$14.75 +0.04 (+0.25%) As of 02/21/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Medifast Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medifast alerts:Sign Up Key Stats Today's Range$14.24▼$14.9450-Day Range$14.34▼$19.1452-Week Range$13.57▼$42.68Volume329,782 shsAverage Volume232,291 shsMarket Capitalization$160.96 millionP/E Ratio81.74Dividend YieldN/APrice Target$16.50Consensus RatingHold Company OverviewMedifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More… Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 71% of companies evaluated by MarketBeat, and ranked 68th out of 151 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 81.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 81.74, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 16.38.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.91% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Medifast has recently decreased by 2.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted12.91% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Medifast has recently decreased by 2.14%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.22 News SentimentMedifast has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Medifast this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Medifast to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMedifast Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 20 at 7:14 AM | finance.yahoo.comQ4 2024 Medifast Inc Earnings CallFebruary 20 at 2:07 AM | finance.yahoo.comEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?February 22, 2025 | Colonial Metals (Ad)Medifast sees Q1 revenue $100M-$120MFebruary 20 at 2:07 AM | markets.businessinsider.comMedifast reports Q4 adjusted EPS 10c vs. $1.09 last yearFebruary 20 at 2:07 AM | markets.businessinsider.comMedifast, Inc. (NYSE:MED) Q4 2024 Earnings Call TranscriptFebruary 20 at 2:07 AM | msn.comMedifast Faces Revenue Challenges Amid New Product LaunchFebruary 19 at 7:36 PM | tipranks.comMedifast Inc (MED) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...February 19 at 2:24 AM | gurufocus.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $17.62 at the beginning of the year. Since then, MED stock has decreased by 16.5% and is now trading at $14.7130. View the best growth stocks for 2025 here. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) announced its earnings results on Tuesday, February, 18th. The specialty retailer reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.26. The specialty retailer earned $119 million during the quarter, compared to analyst estimates of $114.25 million. Medifast had a trailing twelve-month return on equity of 10.64% and a net margin of 0.35%. Who are Medifast's major shareholders? Medifast's top institutional shareholders include Renaissance Technologies LLC (8.26%), Federated Hermes Inc. (2.55%), Bank of America Corp DE (2.52%) and Geode Capital Management LLC (2.25%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings2/18/2025Today2/21/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$16.50 Low Stock Price Target$16.50 Potential Upside/Downside+12.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio81.74 Forward P/E Ratio28.85 P/E GrowthN/ANet Income$99.42 million Net Margins0.35% Pretax Margin0.63% Return on Equity10.64% Return on Assets7.57% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio2.55 Sales & Book Value Annual Sales$602.46 million Price / Sales0.27 Cash Flow$3.02 per share Price / Cash Flow4.87 Book Value$19.21 per share Price / Book0.77Miscellaneous Outstanding Shares10,940,000Free Float10,665,000Market Cap$160.96 million OptionableOptionable Beta1.14 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NYSE:MED) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.